Targeted p53 Gene Therapy-Mediated Radiosensitization and Chemosensitization
作者： Esther H. Chang , Kathleen F. Pirollo , Liang Xu
DOI: 10.1007/978-1-59259-218-0_29
关键词: Cancer 、 Suppressor 、 Gene expression 、 Cancer cell 、 Gene 、 Cancer research 、 Cationic liposome 、 Medicine 、 Genetic enhancement 、 Tumor suppressor gene
摘要: Gene therapy is based on restoring a missing or defective cellular function by delivering and expressing gene encoding the protein responsible for that function. Initially, was envisioned as potential means to correct inherited mono-genic defects. This remains an active area of research, number human clinical trials this approach are ongoing (1–3). In addition monogenic defects, being applied other types diseases. chapter describes therapy, it used in armamentarium war against cancer. More than 100 oncology-related involving have been approved worldwide (4). These therapeutic protocols include expression cytokines enhance immunogenicity, genes prodrug activating enzymes, resulting increased drug sensitivity (e.g., HSVTK/gancyclovir), resistance MDR-1 protect normal bone marrow cells) (5) restoration function(s) tumor suppressor genes. wherein exogenous expressed with intent, suppression antisense molecules targeting oncogenes) also ongoing. The focus current nonviral delivery functional (encoding p53) cancer cells.
springer.com
sci-hub.st 参考文章(136)
Harold N. Keer, James M. Kozlowski, Yvonne C. Tsai, Chung Lee, Robert N. McEwan, John T. Grayhack, Elevated Transferrin Receptor Content in Human Prostate Cancer Cell Lines Assessed in Vitro and in Vivo Journal of Urology. ,vol. 143, pp. 381- 385 ,(1990) , 10.1016/S0022-5347(17)39970-6
K N Wills, M P Harris, W Hancock, S Sutjipto, R J Gregory, H M Shepard, D E Johnson, D C Maneval, D Cornell, Adenovirus-mediated p53 gene transfer inhibits growth of human tumor cells expressing mutant p53 protein. Cancer Gene Therapy. ,vol. 3, pp. 121- 130 ,(1996)
Theresa M. Allen, Liposomes Opportunities in Drug Delivery Drugs. ,vol. 54, pp. 8- 14 ,(1997) , 10.2165/00003495-199700544-00004
L L Nielsen, D C Maneval, P53 tumor suppressor gene therapy for cancer. Cancer Gene Therapy. ,vol. 5, pp. 52- 63 ,(1998)
John M. Skibber, Francis R. Spitz, Jack A. Roth, James Cusack, Dao Nguyen, Richard J. Cristiano, In vivo adenovirus-mediated p53 tumor suppressor gene therapy for colorectal cancer. Anticancer Research. ,vol. 16, pp. 3415- 3422 ,(1996)
Makio Wada, Claus R Bartram, Haruhiko Nakamura, Misao Hachiya, Dan-Lin Chen, Jeff Borenstein, Carl W Miller, Leopold Ludwig, Thomas E Hansen-Hagge, Wolf-Dieter Ludwig, None, Analysis of p53 mutations in a large series of lymphoid hematologic malignancies of childhood Blood. ,vol. 82, pp. 3163- 3169 ,(1993) , 10.1182/BLOOD.V82.10.3163.3163
Gary L. Clayman, Helmuth Goepfert, Jack A. Roth, Dorothy L. Taylor, Wei-Wei Zhang, Ta-Jen Liu, Growth Suppression of Human Head and Neck Cancer Cells by the Introduction of a Wild-Type p53 Gene via a Recombinant Adenovirus Cancer Research. ,vol. 54, pp. 3662- 3667 ,(1994)
D S Hawkins, G W Demers, D A Galloway, Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Research. ,vol. 56, pp. 892- 898 ,(1996)
Amanda J. McIlwrath, Robert Brown, Paul A. Vasey, Gillian M. Ross, Cell cycle arrests and radiosensitivity of human tumor cell lines: dependence on wild-type p53 for radiosensitivity. Cancer Research. ,vol. 54, pp. 3718- 3722 ,(1994)
Kurt W. Kohn, Joany Jackman, Ian Magrath, Kishor Bhatia, Daniel Jondle, Patrick M. O'Connor, Role of the p53 tumor suppressor gene in cell cycle arrest and radiosensitivity of Burkitt's lymphoma cell lines Cancer Research. ,vol. 53, pp. 4776- 4780 ,(1993)